Loading clinical trials...
Loading clinical trials...
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sirion Therapeutics, Inc.
Collaborators
NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07230834 · Geographic Atrophy (GA)
NCT07441642 · Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07144137 · Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT06779773 · Geographic Atrophy, Macular Degeneration
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions